Sutent (sunitinib malate, manufactured by Pfizer) is a multiple receptor tyrosine kinase inhibitor (what scientists call “TKI”). Sutent has been approved by the European Union for treatment of advanced and/or metastatic renal cell carcinoma (MRCC). Sutent is an oral therapy and its mechanism of action is antiangiogensis. In other words, the drug starves cancer cells by (More …)